RANI THERAPEUTICS HOLDINGS-A (RANI) Stock Price & Overview
NASDAQ:RANI • US7530181004
Current stock price
The current stock price of RANI is 0.9901 USD. Today RANI is up by 1.68%. In the past month the price decreased by -13.83%. In the past year, price decreased by -13.06%.
RANI Key Statistics
- Market Cap
- 122.465M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.59
- Dividend Yield
- N/A
RANI Stock Performance
RANI Stock Chart
RANI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to RANI. When comparing the yearly performance of all stocks, RANI is a bad performer in the overall market: 87.23% of all stocks are doing better.
RANI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RANI. The financial health of RANI is average, but there are quite some concerns on its profitability.
RANI Earnings
On March 26, 2026 RANI reported an EPS of -0.07 and a revenue of 1.46M. The company missed EPS expectations (-2.94% surprise) and missed revenue expectations (-71.35% surprise).
RANI Forecast & Estimates
9 analysts have analysed RANI and the average price target is 7.14 USD. This implies a price increase of 621.14% is expected in the next year compared to the current price of 0.9901.
For the next year, analysts expect an EPS growth of 64.27% and a revenue growth 15.69% for RANI
RANI Groups
Sector & Classification
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS increased by 44.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.62% | ||
| ROE | -89.89% | ||
| Debt/Equity | 0 |
RANI Ownership
RANI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.5 | 869.14B | ||
| JNJ | JOHNSON & JOHNSON | 17.8 | 555.642B | ||
| MRK | MERCK & CO. INC. | 22.17 | 289.223B | ||
| PFE | PFIZER INC | 9.17 | 156.544B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.28 | 120.728B | ||
| ZTS | ZOETIS INC | 17.2 | 51.606B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 28.443B | ||
| VTRS | VIATRIS INC | 5.98 | 17.315B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.01 | 11.825B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.651B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.206B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.087B | ||
| CORT | CORCEPT THERAPEUTICS INC | 82.69 | 4.929B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
IPO: 2021-07-30
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 70
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you describe the business of RANI THERAPEUTICS HOLDINGS-A?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
What is the stock price of RANI THERAPEUTICS HOLDINGS-A today?
The current stock price of RANI is 0.9901 USD. The price increased by 1.68% in the last trading session.
Does RANI THERAPEUTICS HOLDINGS-A pay dividends?
RANI does not pay a dividend.
What is the ChartMill technical and fundamental rating of RANI stock?
RANI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists RANI stock?
RANI stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of RANI THERAPEUTICS HOLDINGS-A (RANI)?
RANI THERAPEUTICS HOLDINGS-A (RANI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
Is RANI THERAPEUTICS HOLDINGS-A (RANI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RANI.